Oaktree Specialty Lending Corporation (OCSL)
NASDAQ: OCSL · IEX Real-Time Price · USD
19.43
+0.14 (0.73%)
Apr 17, 2024, 4:00 PM EDT - Market closed

Company Description

Oaktree Specialty Lending Corporation is a business development company.

The fund specializing in investments in middle market, bridge financing, first and second lien debt financing, unsecured and mezzanine loan, mezzanine debt, senior and junior secured debt, expansions, sponsor-led acquisitions, preferred equity, and management buyouts in small and mid-sized companies.

It seeks to invest in education services, business services, retail and consumer, healthcare, manufacturing, food and restaurants, construction and engineering.

The firm also seeks investment in media, advertising sectors, software, IT services, pharmaceuticals, biotechnology, real estate management and development, chemicals, machinery, and internet and direct marketing retail sectors.

It invests between $5 million to $75 million principally in the form of one-stop, first lien, and second lien debt investments, which may include an equity co-investment component in companies.

The firm invest in companies having enterprise value between $20 million and $150 million and EBITDA between $3 million and $50 million.

The fund has a hold size of up to $75 million and may underwrite transactions up to $100 million. It primarily invests in North America.

The fund seeks to be a lead investor in its portfolio companies.

Oaktree Specialty Lending Corporation
Oaktree Specialty Lending logo
Country United States
IPO Date Jun 12, 2008
Industry Credit Services
Sector Financials
CEO Armen Panossian J.D.

Contact Details

Address:
333 South Grand Avenue, 28th Floor
Los Angles, California 90071
United States
Phone (213) 830-6300
Website oaktreespecialtylending.com

Stock Details

Ticker Symbol OCSL
Exchange NASDAQ
Fiscal Year October - September
Reporting Currency USD
CIK Code 0001414932
CUSIP Number 67401P108
ISIN Number US67401P4054
Employer ID 26-1219283

Key Executives

Name Position
Armen Panossian J.D. Chief Executive Officer and Chief Investment Officer
Mathew M. Pendo President
Aman Kumar Managing Director and Co-Portfolio Manager of Life Sciences Direct Lending
Raghav Khanna Managing Director and Co-Portfolio Manager
Christopher McKown MD,Chief Financial Officer and Treasurer
Matthew Stewart C.F.A., CPA MD and Chief Operating Officer
Michael Mosticchio Investor Relations
Mary Gallegly MD,General Counsel and Secretary
Ashley Pak Chief Compliance Officer
Sandeep Kumar Khorana Managing Director of Origination

Latest SEC Filings

Date Type Title
Mar 5, 2024 8-K Current Report
Feb 13, 2024 40-APP Filing
Feb 1, 2024 8-K Current Report
Feb 1, 2024 10-Q Quarterly Report
Jan 30, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jan 19, 2024 DEF 14A Other definitive proxy statements
Jan 19, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jan 10, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jan 10, 2024 DEF 14A Other definitive proxy statements
Dec 22, 2023 PRE 14A Other preliminary proxy statements